Polyclonal Antibody to Nitric Oxide Synthase 3, Endothelial (NOS3)
Code | Size | Price |
---|
PAA868Ra01-20ul | 20ul | £86.00 |
Quantity:
PAA868Ra01-100ul | 100ul | £158.00 |
Quantity:
PAA868Ra01-200ul | 200ul | £214.00 |
Quantity:
PAA868Ra01-1ml | 1ml | £488.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
NOS3; ECNOS; NOS III; E-NOS; C-NOS; ENOS; CNOS; Constitutive NOS; Nitric Oxide Synthase 3, Endothelial
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Endothelial NOS
Reactivity:
Hu;Mu;Rb;Ca;Po;Bo;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.3-3ug/mL<br/>Immunohistochemistry: 5-30ug/mL<br/>Immunocytochemistry: 5-30ug/mL<br/>Optimal working dilutions must be determined by end user.
References
https://www.degruyter.com/document/doi/10.1515/jbcpp-2021-0080/html; https://dergipark.org.tr/en/pub/jfpanu/issue/73490/1131302;
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Nitric Oxide Synthase 3, Endothelial (NOS3) | RPA868Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||